Get the Stockscreener App
8.11
4.81%
-0.41
Pre-market:
7.51
-0.60
-7.40%
Stoke Therapeutics Inc Stock (STOK) Latest News
Rhumbline Advisers Acquires 2,787 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Los Angeles Capital Management LLC Has $479,000 Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke, Biogen team to advance zorevunersen for Dravet patients - Dravet Syndrome News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug - MSN
Stoke Therapeutics to Present at Upcoming Investor Conferences in March - Business Wire
Wedbush Research Analysts Cut Earnings Estimates for STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Buy” from Brokerages - Defense World
What is HC Wainwright's Estimate for STOK FY2025 Earnings? - MarketBeat
Stoke Therapeutics' (STOK) Buy Rating Reiterated at Chardan Capital - MarketBeat
Equities Analysts Offer Predictions for STOK Q1 Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
HC Wainwright Has Bullish Forecast for STOK FY2025 Earnings - Defense World
Trading (STOK) With Integrated Risk Controls - Stock Traders Daily
Stoke Therapeutics’ Collaboration with BioGen - Global Legal Chronicle
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from Chardan Capital - Defense World
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MSN
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% – Here’s Why - Defense World
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright - Defense World
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - BioSpace
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - Insights
Biogen and Stoke Therapeutics Enter into Collaboration to - GlobeNewswire
Biogen’s Bold Bet: A New Hope for Dravet Syndrome Shines Bright - Smartphone Magazine
Biogen, Stoke partner for Dravet syndrome treatment By Investing.com - Investing.com Nigeria
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Benzinga
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
BTIG maintains Stoke Therapeutics stock with $29 target By Investing.com - Investing.com UK
HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating - Marketscreener.com
Biogen And Stoke Therapeutics Enter Into Collaboration -February 18, 2025 at 10:00 am EST - Marketscreener.com
Strategic Collaboration and Positive Clinical Data Propel Stoke Therapeutics to a Buy Rating - TipRanks
Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen -February 18, 2025 at 09:39 am EST - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com India
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha
Sector Update: Health Care Stocks Softer Wednesday Afternoon -February 12, 2025 at 01:47 pm EST - Marketscreener.com
SG Americas Securities LLC Sells 4,149 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Sector Update: Health Care Stocks Retreat Late Afternoon -February 12, 2025 at 03:54 pm EST - Marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%Here's Why - MarketBeat
Long Term Trading Analysis for (STOK) - Stock Traders Daily
Understanding the 7.51% Volatility Levels of Stoke Therapeutics Inc’s (STOK) Stock in the Past 30 Days - The News Heater
STOK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.2%Here's Why - MarketBeat
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? - MSN
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):